BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.

Biohaven Pharmaceutical Holding Company Ltd.

Equities

BHVN

VGG111961055

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:02 17/07/2024 BST			5-day change	1st Jan Change
36.29 ^USD	-4.35%		+0.30%	-76.09%

05-31	Biohaven Insider Bought Shares Worth $996,240, According to a Recent SEC Filing	MT
05-15	Biohaven Insider Bought Shares Worth $512,877, According to a Recent SEC Filing	MT

Portage Biotech Inc. (OTCPK:PTGE.F) acquired 54% stake in Biohaven Pharmaceutical Holding Company Limited for $2416.

January 06, 2014 at 04:00 am

Portage Biotech Inc. (OTCPK:PTGE.F) acquired 54% stake in Biohaven Pharmaceutical Holding Company Limited for $2416 on January 6, 2014. Under the terms of the transaction, $1208 will be paid upfront and the balance in three installments over the next eleven months. Portage Biotech issued 0.011504 million shares to Biohaven.

Portage Biotech Inc. (OTCPK:PTGE.F) completed the acquisition of 54% stake in Biohaven Pharmaceutical Holding Company Limited on January 6, 2014.

Latest news about Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Insider Bought Shares Worth $996,240, According to a Recent SEC Filing	05-31	MT
Biohaven Insider Bought Shares Worth $512,877, According to a Recent SEC Filing	05-15	MT
Biohaven Insider Bought Shares Worth $1,002,470, According to a Recent SEC Filing	05-14	MT
Biohaven Shares Fall as Q1 Loss Widens, Misses Estimates	05-10	MT
Biohaven Insider Bought Shares Worth $999,169, According to a Recent SEC Filing	04-25	MT
Biohaven Shares Rise After Closing of Public Offering, Disclosure of Stock Purchase by CEO	04-23	MT
UBS Adjusts Biohaven Price Target to $60 From $59, Maintains Buy Rating	04-23	MT
Biohaven Insider Bought Shares Worth $7,999,961, According to a Recent SEC Filing	04-23	MT
Biohaven Insider Bought Shares Worth $4,999,991, According to a Recent SEC Filing	04-23	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	04-18	MT
Biohaven Prices $230 Million Public Share Offering	04-18	MT
Biohaven Launches $200 Million Common Stock Offering	04-17	MT
HC Wainwright Adjusts Biohaven's Price Target to $63 From $50, Maintains Buy Rating	03-04	MT
TD Cowen Ups Price Target on Biohaven to $55 From $35, Keeps Outperform Rating	03-01	MT
RBC Trims Price Target on Biohaven to $61 From $62, Keeps Outperform, Speculative Risk	03-01	MT
Biohaven Q4 Non-GAAP Net Loss Widens, Shares Fall After-Hours	02-29	MT
RBC Initiates Biohaven at Outperform With Speculative Risk, Sets Price Target at $62, Sees 'Significant Value to Be Unlocked' Over Long Term	02-16	MT
UBS Adjusts Initiates Biohaven Pharmaceutical Holding With Buy Rating, $59 Price Target	02-06	MT
Biohaven Insider Sold Shares Worth $459,663, According to a Recent SEC Filing	01-02	MT
Baird Starts Biohaven Pharmaceutical With Outperform Rating, $58 Price Target	12-08	MT
JPMorgan Adjusts Biohaven Pharmaceutical Price Target to $32 From $26, Maintains Overweight Rating	11-20	MT
Piper Sandler Adjusts Price Target on Biohaven Pharmaceutical to $36 From $29, Keeps Overweight Rating	11-15	MT
Biohaven Pharmaceutical Q3 Net Loss Narrows	11-14	MT
Biohaven Pharmaceutical Says Obesity Treatment Candidate Reduces Fat, Improves Lean Mass	16/10/23	MT
Biohaven Insider Bought Shares Worth $9,999,990, According to a Recent SEC Filing	11/10/23	MT

Chart Biohaven Pharmaceutical Holding Company Ltd.

Duration

Period

Chart Biohaven Pharmaceutical Holding Company Ltd.

More charts

Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based commercial-stage biopharmaceutical company. The Company has a portfolio of therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. The Company's Neuroinnovation portfolio includes NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine and a pipeline of product candidates across five platforms: calcitonin gene related peptide (CGRP) receptor antagonism for the acute and preventive treatment of migraine as well as other pain-related disorders and non-migraine indications; glutamate modulation for obsessive-compulsive disorder (OCD); myeloperoxidase (MPO) inhibition for multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS); Kv7 Ion Channel Activators (Kv7) to target indications including epilepsy, pain disorders and effective disorders; and Myostatin offers a natural protein that limits skeletal muscle growth.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.	-76.09%	541M
MODERNA, INC.	+24.74%	47.54B
IQVIA HOLDINGS INC.	-0.47%	41.96B
LONZA GROUP AG	+48.83%	41.55B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	30.36B
ICON PUBLIC LIMITED COMPANY	+17.96%	27.61B
CELLTRION, INC.	-4.47%	28.7B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.7B
MEDPACE HOLDINGS, INC.	+42.56%	13.51B
BIO-TECHNE CORPORATION	+1.46%	12.34B

Other Biotechnology & Medical Research